What are Phosphodiesterase 4 inhibitor drugs?

Phosphodiesterase 4 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Phosphodiesterase 4). 0 are currently marketed, with 3 more in clinical development.

Phosphodiesterase 4 inhibitor

0 marketed 3 in Phase 3

This page covers all Phosphodiesterase 4 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Phosphodiesterase 4, Phosphodiesterase-4, phosphodiesterase 4.

Targets

Phosphodiesterase 4 · Phosphodiesterase-4 · phosphodiesterase 4 · Phosphodiesterase-4 (PDE4)

Phase 3 pipeline (3)

Roflumilast Cream 0.15% · Arcutis Biotherapeutics, Inc. · Immunology
Roflumilast is a phosphodiesterase 4 inhibitor that reduces inflammation by blocking the action of phosphodiesterase 4.
Roflumilast Cream 0.3% · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Respiratory
Roflumilast is a phosphodiesterase-4 inhibitor, which reduces inflammation by inhibiting the production of pro-inflammatory cytokines.
Topical roflumilast · Arcutis Biotherapeutics, Inc. · Dermatology
Topical roflumilast is a phosphodiesterase 4 inhibitor that reduces inflammation in the skin.